Archive for October, 2010

Bad boards of directors kill more companies than bad management…

A side-comment at the Mid Atlantic Biotech conference really got me thinking. One of the panelists mentioned as an aside that she thought that more companies failed due to bad boards than due to bad management (she preferred not to be named). The board of directors is more than a set of advisors to company […]

Next DCbiotech meeting: Tuesday November 2nd

The next DCbiotech meeting will be at the Marriott Renaissance Washington DC Downtown Hotel on November 2nd  2010. The hotel is at 999 Ninth Street NW, and we’ll be meeting in the Mixx bar from 6:30-8:30pm. To facilitate finding the group, you may want to check out my photo on the about page. Where: Mixx […]

Bringing Better Medicines to Market Faster, an Interview with Expert John Avellanet

Positive reviews of the book, Get to Market Now! Turn FDA Compliance into a Competitive Edge in the Era of Personalized Medicine, have been appearing since the book’s publication earlier this year.  The BiotechBlog sat down with author John Avellanet for a discussion of the book’s appeal. BB:   Why do you think the book is […]

Drug Patent Expirations in October 2010

Drug Patent Expirations in October 2010 *Drugs may be covered by multiple patents Tradename Applicant Generic Name Patent Number Patent Expiration ORGARAN Organon Usa Inc danaparoid sodium 5,164,377 Oct 3, 2010 MIRAPEX ER Boehringer Ingelheim pramipexole dihydrochloride 4,886,812 Oct 8, 2010 MIRAPEX Boehringer Ingelheim pramipexole dihydrochloride 4,886,812 Oct 8, 2010 CLIMARA PRO Bayer Hlthcare estradiol; […]

Developing a biotechnology cluster in Japan

The panel on applying Design Thinking to biotechnology was well received, and I look forward to writing up my observations. I’m now in Japan for a workshop on developing a biotechnology cluster. The U.S. biotechnology industry – the largest in the world – was basically developed with  strong  support from Japanese pharmaceutical and brewing companies. […]